Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review

Abstract Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous disease, with no standard treatment. We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010. All patients were transfusion dependent at the time of initiat...

Full description

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 36; no. 8; pp. 1071 - 1073
Main Authors Thorpe, Michael, Montalvão, Ana, Pierdomenico, Francesca, Moita, Filipa, Almeida, António
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.08.2012
Subjects
5-Azacitidine
Adult
Aged
Antimetabolites, Antineoplastic - therapeutic use
Azacitidine - therapeutic use
Chronic myelomonocytic leukemia
Female
Hematology, Oncology and Palliative Medicine
Humans
Hypomethylating agents
Leukemia, Myelomonocytic, Chronic - diagnosis
Leukemia, Myelomonocytic, Chronic - drug therapy
Male
Middle Aged
Myelodysplasia
Prognosis
Treatment Outcome
5-Azacitidine
Myelodysplasia
Chronic myelomonocytic leukemia
Hypomethylating agents
Online AccessGet full text

Cover

More Information
Summary:Abstract Chronic myelomonocytic leukemia (CMML) is a clinically heterogeneous disease, with no standard treatment. We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010. All patients were transfusion dependent at the time of initiation of therapy. The overall response rate was 60%. Responses were obtained in 2/3 of the patients with proliferative CMML. The median survival from start of therapy was 20 months. AZA treatment was well-tolerated and associated with a significant response rate in all forms of the disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Review-2
ObjectType-Case Study-4
ObjectType-Feature-5
ObjectType-Report-3
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2012.04.024